Related Experiment Video

Updated: Aug 7, 2026

Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection
06:11

Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection

Published on: May 17, 2024

Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind, randomized,

William H Lagarde1, Frank P Barrows, Marsha L Davenport

  • 1Department of Pediatrics, The University of North Carolina at Chapel Hill, NC 27599-7039, USA.

Pediatric Diabetes
|June 22, 2006
PubMed

Insights

Continuous glucose-monitoring system (CGMS) use in children with type 1 diabetes mellitus (T1DM) may improve metabolic control. This study found CGMS improved glycemic control without increasing hypoglycemia risk in pediatric T1DM patients.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Technology
  • Metabolic Control

Background:

  • Tight glycemic control in type 1 diabetes mellitus (T1DM) reduces long-term complications but elevates hypoglycemia risk.
  • Continuous glucose-monitoring systems (CGMS) offer frequent blood glucose (BG) readings, with established accuracy in adults.
  • Limited data exist on CGMS efficacy and safety in pediatric populations.

Purpose of the Study:

  • To evaluate the impact of CGMS on metabolic control in children with T1DM.
  • To determine if CGMS use improves glycemic management in pediatric T1DM patients.

Main Methods:

  • A single-blind, randomized controlled trial involving 27 children with T1DM (ages 7-17).
  • Participants were randomized into an intervention group (CGMS + SMBG) or a control group (SMBG only).
  • CGMS was used for 72-h periods at 0, 2, and 4 months, with HbA1c measured at 0, 2, 4, and 6 months.

Main Results:

  • The intervention group showed a statistically significant decrease in HbA1c (0.61 +/- 0.68%, p=0.03) from baseline.
  • While the intervention group had lower final HbA1c levels (7.8% vs 8.6%, p=0.02), the overall change between groups was not statistically significant (p=0.13).
  • No significant differences in hypoglycemia (AUC(<70)) were observed between groups (p=0.18).

Conclusions:

  • CGMS use shows potential for improving metabolic control in children with T1DM.
  • The study suggests CGMS can be used safely in pediatric T1DM patients without increasing hypoglycemia risk.
Abstract

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...